Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins. Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news

Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia
SUZHOU, China and ROCKVILLE, Md., Sept. 7, 2020 -- (Healthcare Sales & Marketing Network) -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),... Biopharmaceuticals, Oncology, FDA Ascentage Pharma, APG-2575, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 7, 2020 Category: Pharmaceuticals Source Type: news

The Guardian view on African success: a step closer to conquering polio | Editorial
We are tantalisingly close to eradicating the disease. Things may slip backwards because of science, thugs and exponents of ignorancePolio arrives, if it announces itself at all, as a high temperature. Or a sore throat. Maybe a headache, or an upset stomach. It can go within a week or so, and be mistaken for flu. It is transmitted by poor hygiene, largely affects children under five, and many don ’t realise they’ve had it. In 5-10% of cases, however, the virus affects the nerves, paralysing the legs in particular; sometimes it reaches the lungs. For most, this is temporary. For others –30 years ago, this ...
Source: Guardian Unlimited Science - August 30, 2020 Category: Science Authors: Editorial Tags: Polio Vaccines and immunisation Children Pakistan Afghanistan Hepatitis B Taliban Coronavirus outbreak Infectious diseases Health Medical research Science South and Central Asia Society Source Type: news

Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan, December 6, 2019-March 15, 2020
This report describes a funding program in Uzbekistan designed to identify and treat cases of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection at a lowered cost with the goal of meeting the World Health Organization's targets to eliminate HBC and HCV infection. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - August 27, 2020 Category: American Health Tags: Hepatitis B Hepatitis C MMWR Morbidity & Mortality Weekly Report Source Type: news

The Role of the Pharmacist in Preventing Hepatitis B in the Context of the Opioid Crisis
(Source: CDC Preventing Chronic Disease)
Source: CDC Preventing Chronic Disease - August 20, 2020 Category: International Medicine & Public Health Tags: Public Health Source Type: news

Lack of continuous infectious disease pandemic research endangers responses
(American Associates, Ben-Gurion University of the Negev) The coronavirus was also studied considerably less than blood borne viruses like Hepatitis B or C and H.I.V. and its research community has less prolific researchers than the other investigated diseases. This translates into limited collaborations and a non-sustained investment in research on coronaviruses. Such a short-lived investment also reduces funding and may slow down important developments such as new drugs, vaccines or preventive strategies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 17, 2020 Category: International Medicine & Public Health Source Type: news

Busting Up the Infection Cycle of Hepatitis B
(University of Delaware) Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the " spiky ball " that encloses its genetic blueprint. They looked at how the capsid--a protein shell that protects the blueprint and also drives the delivery of it to infect a host cell--assembles itself. The capsid is an important target in developing drugs to treat hepatitis B, a life-threatening and incurable infection that afflicts more than 250 million people worldwide. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 13, 2020 Category: Biology Source Type: news

Hepatitis B: Natural controllers shed light on immunity mechanisms
(Institut Pasteur) To improve our understanding of the antibody response conferring protection against HBV infection, scientists from the Institut Pasteur and Inserm, in collaboration with the Roche Innovation Center in Switzerland, produced and characterized human monoclonal antibodies specific to viral envelope antigens, referred as HBsAg, from blood memory B cells isolated from HBV vaccinees and natural controllers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 13, 2020 Category: Biology Source Type: news

Hepatitis Screening Now for All Patients With Cancer on Therapy Hepatitis Screening Now for All Patients With Cancer on Therapy
All patients with cancer who are candidates for systemic therapy should be screened for hepatitis B, says the American Society of Clinical Oncology.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 5, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

US obesity epidemic could undermine effectiveness of a Covid-19 vaccine
Vaccines protecting against influenza, hepatitis B and rabies are less effective for obese people. As scientists develop a Covid-19 vaccine, experts say obesity could be an impediment, a sobering prospect for the US, where nearly half of all adults are obese. (Source: CNN.com - Health)
Source: CNN.com - Health - August 5, 2020 Category: Consumer Health News Source Type: news

First drug for hepatitis D has been approved by european commission
(German Center for Infection Research) The European Commission has approved Hepcludex for the treatment of chronic hepatitis D infection / Successful translation of basic research into clinical applications / entry blocker also demonstrates effectiveness against hepatitis B (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 5, 2020 Category: Biology Source Type: news

Birth dose of hepatitis B vaccine cost effective in Ethiopia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2020 Category: Drugs & Pharmacology Source Type: news

Progress Toward Hepatitis B Control - South-East Asia Region, 2016-2019
This report describes progress of countries in the World Health Organization's South-East Asia region toward reaching 90% hepatitis B vaccination coverage. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - July 30, 2020 Category: American Health Tags: Hepatitis B Hepatitis B Screening Hepatitis B Vaccination MMWR Morbidity & Mortality Weekly Report Source Type: news

Zambia: Zambia Joins the Global Community to Commemorate the World Hepatitis Day
[WHO] To mark the commemoration of the World Hepatitis Day 2020, the World Health Organization has called for a global and united effort to eliminate viral hepatitis as a public health threat by 2030. More than 1.3 million people die annually as a result of Hepatitis B and C. Zambia has therefore joined the global community to commemorate World Hepatitis Day under the theme "Hepatitis free future". The theme highlights the importance of preventing mother-to-child transmission of Hepatitis B and scaling (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 30, 2020 Category: African Health Source Type: news

Nigeria: Over 20 Million Nigerians Infected With Hepatitis - Minister
[Premium Times] About 20 million Nigerian are chronically infected with hepatitis B and C, the minister of health, Osagie Ehanire, said on Tuesday. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 30, 2020 Category: African Health Source Type: news

Spread of hepatitis B in children under five, lowest in decades: WHO
The global prevalence of potentially-deadly hepatitis B in children under age five, dropped to under one per cent in 2019 – down from five per cent in the pre-vaccine decades between the 1980s and early 2000s, the World Health Organization (WHO) reported on Monday. (Source: UN News Centre - Health, Poverty, Food Security)
Source: UN News Centre - Health, Poverty, Food Security - July 27, 2020 Category: International Medicine & Public Health Source Type: news

Viral hepatitis: Europe needs to close the testing gap
(European Centre for Disease Prevention and Control (ECDC)) Approximately four in five people living with hepatitis B and three out of four people with hepatitis C infection across the European Union and European Economic Area (EU/EEA) and the UK have not yet been diagnosed. This is a major obstacle on the way towards the Sustainable Development Goal (SDG) for health in 2030 as highlighted by ECDC on occasion of World Hepatitis Day. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 27, 2020 Category: Infectious Diseases Source Type: news

Closing the gap: finding undiagnosed hepatitis C infections after blood transfusions
(European Centre for Disease Prevention and Control (ECDC)) What is the incidence of viral hepatitis caused by blood transfusions before and after Sweden introduced screening of blood in the early 1990s? In an article published in Eurosurveillance ahead of World Hepatitis Day on 28 July, the authors also try to estimate how many people of those who were infected with hepatitis B and C through blood transfusion still live with undiagnosed hepatitis. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 23, 2020 Category: Infectious Diseases Source Type: news

Linkage to and Retention in Care Among Refugees With HBV Linkage to and Retention in Care Among Refugees With HBV
This report assessed a quality improvement intervention and outreach program for refugees with hepatitis B infection at three U.S. refugee screening sites.Morbidity & Mortality Weekly Report (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 20, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 10, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Updated Guidance Provided for Safe Solid Organ Transplantation
TUESDAY, June 30, 2020 -- Updated recommendations for reducing transmission of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) through transplantation include universal solid organ donor nucleic acid testing, according to research... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 30, 2020 Category: Pharmaceuticals Source Type: news

Researchers identify multiple molecules that shut down SARS-Cov-2 polymerase reaction
(Columbia University School of Engineering and Applied Science) Researchers at Columbia Engineering and the University of Wisconsin-Madison have identified a library of molecules that shut down the SARS-CoV-2 polymerase reaction, a key step that establishes the potential of these molecules as lead compounds to be further modified for the development of COVID-19 therapeutics. Five of these molecules are already FDA-approved for use in the treatment of other viral infections including HIV/AIDS, cytomegalovirus, and hepatitis B. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 30, 2020 Category: Infectious Diseases Source Type: news

RECOMMENDATIONS and REPORTS: Assessing Solid Organ Donors and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection - U.S. Public Health Service Guideline, 2020
This report describes the June 2020 U.S. Public Health Service guidelines which recommend actions healthcare providers can take before and after transplant to minimize the risk of infection (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - June 25, 2020 Category: American Health Tags: Hepatitis Hepatitis B Hepatitis C HIV/AIDS MMWR Morbidity & Mortality Weekly Report Organ Transplants Source Type: news

FDA approves Roche ’s Tecentriq in combination with Avastin for people with the most common form of liver cancer
Basel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received p rior systemic therapy.“We’re excited that today’s approval of Tecentriq in combination with Avastin for unresectable or metastatic hepatocellular carcinoma brings a cancer immunotherapy option to people with this aggressive form of liver cancer,” said Levi Garraway, M.D., Ph....
Source: Roche Media News - June 2, 2020 Category: Pharmaceuticals Source Type: news

Evaluation of a Program to Improve Linkage to and Retention in Care Among Refugees with Hepatitis B Virus Infection - Three U.S. Cities, 2006-2018
Identification and management of hepatitis B infection in children and adults from countries with a high prevalence of infection, including refugees, is important for protecting their health and preventing transmission to others. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - May 28, 2020 Category: American Health Tags: Hepatitis B MMWR Morbidity & Mortality Weekly Report Source Type: news

Why this Bucks County biopharm firm's stock is up more than 26% Tuesday
The Warminster company's goal is to find a cure for hepatitis B. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 19, 2020 Category: Pharmaceuticals Authors: John George Source Type: news

First-in-class drug candidate developed through NFCR funding commences phase IIB clinical trials
(National Foundation for Cancer Research) The first patients have been dosed in a multi-regional Phase IIB randomized, placebo-controlled clinical trial for the treatment of hepatitis B-associated liver cancer. Being tested in the first line setting is a first-in-class botanical drug candidate, YIV-906, whose development has been supported for two decades by the National Foundation for Cancer Research -- which has supported its principal investigator, Yale University's Dr. Yung-Chi Cheng, for three decades. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2020 Category: Cancer & Oncology Source Type: news

What Are Potential Complications of Tattooing?
Discussion “Tattooing of skin via deposition of pigment particles and ink ingredients in the dermis changes normal skin into abnormal skin. Fortunately, this often causes no harm and no disease, although with important exceptions.” Tattoos can be inadvertent from road dirt, gunpowder, pencil graphite etc., but most are desired. Tattoos are common in many cultures and over time..They have been increasing in popularity in the United States over the past few years particularly with a younger, wider and more diverse population. Newsweek reported an 18-country study in 2018 which showed 46% of Americans have a tat...
Source: PediatricEducation.org - May 18, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Child vaccinations down in DR Congo, and COVID-19 is not helping: UNICEF
Fewer children are getting vaccinated in the Democratic Republic of the Congo (DRC) and the COVID-19 pandemic is almost certainly going to make matters worse, the United Nations Children’s Fund (UNICEF) says. If the trend continues, it could trigger a resurgence in deadly childhood diseases such as polio, chickenpox, measles, yellow fever, hepatitis B, diphtheria, tetanus, whooping cough and meningitis. (Source: UN News Centre - Health, Poverty, Food Security)
Source: UN News Centre - Health, Poverty, Food Security - May 15, 2020 Category: International Medicine & Public Health Source Type: news

USPSTF: Screen for HBV Infection in People at Increased Risk
The U.S. Preventive Services Task Force recently issued a draft recommendation statement and draft evidence review on screening for hepatitis B virus infection in nonpregnant adolescents and adults. (Source: AAFP News)
Source: AAFP News - May 12, 2020 Category: Primary Care Source Type: news

USPSTF Recommends Hep B Screening for Those at Increased Risk
TUESDAY, May 5, 2020 -- The U.S. Preventive Services Task Force (USPSTF) recommends screening adolescents and adults at increased risk for hepatitis B virus (HBV) infection. These findings form the basis of a draft recommendation statement published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 5, 2020 Category: Pharmaceuticals Source Type: news

What Are the Complications of Inhalant Abuse?
Discussion Hydrocarbons (HC) are organic compounds that are abused because they produce a euphoric effect, usually quickly, are low cost and easily obtained. They are commonly abused by adolescents and use in the US is either stable or increasing. Volatile HC rapidly distribute throughout the body which produces euphoria in seconds to minutes. There are 3 ways that HC are inhaled: Sniffing – directly inhaling the HC from the container. This has the lowest HC concentration. Huffing – a cloth is saturated with the HC and then the cloth is held to the nose and mouth and inhaled. This has a higher concentration ...
Source: PediatricEducation.org - May 4, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Twinrix (Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 27, 2020 Category: Drugs & Pharmacology Source Type: news

Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA ® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion av...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer
             Basel, 21 April 2020 - Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced US Food and Drug Administration (FDA) approval for the cobas ® HPV test for use on the fully automated, high-throughput cobas® 6800/8800 Systems. The cobas® HPV test identifies women at risk for cervical cancer by detecting the presence of high-risk human papillomavirus (HPV) DNA in cervical samples. Persistent high-risk HPV infections can develop into pre cancerous lesions and, if left untreated, these lesions can progress to cervical cancer.“The approval ...
Source: Roche Media News - April 21, 2020 Category: Pharmaceuticals Source Type: news

Scientists explore using 'own' immune cells to target infectious diseases including COVID-19
(Duke-NUS Medical School) The engineering of specific virus-targeting receptors onto a patient's own immune cells is now being explored by scientists from Duke-NUS Medical School, as a potential therapy for controlling infectious diseases, including the COVID-19-causing virus, SARS-CoV-2. This therapy that has revolutionised the treatment of patients with cancer has also been used in the treatment of other infectious diseases such as Hepatitis B virus, as discussed by the School's researchers in a recent commentary. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 21, 2020 Category: Infectious Diseases Source Type: news

Collaboration Offers FPs Guidance on Hepatitis B Management
A multidisciplinary panel of hepatitis B virus experts has collaborated to produce a new guidance document on HBV prevention, diagnosis and management for family physicians and other primary care clinicians. (Source: AAFP News)
Source: AAFP News - April 8, 2020 Category: Primary Care Source Type: news

FDA accepts Roche ’s New Drug Application for Xofluza (baloxavir marboxil) for the treatment of influenza in children
Basel, 27 March  2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) as well as two supplemental New Drug Applications (sNDA) for Xofluza® (baloxavir marboxil). The FDA accepted a NDA for a new formulation of Xofluza as one-dose granules for oral suspension (2 mg/mL), potentially offering a more convenient option for children and those who have difficulty swallowing. In addition, the application seeks approval of Xofluza for the treatment of acute uncomplicated influenza in otherwise healthy children aged one to l ess th...
Source: Roche Investor Update - March 27, 2020 Category: Pharmaceuticals Source Type: news

CDC: Prevalence of Any Past, Present Hep B Infection 4.3 Percent
WEDNESDAY, March 25, 2020 -- The prevalence of any past or present hepatitis B virus (HBV) infection was 4.3 percent among U.S. adults during 2015 to 2018, according to a March data brief published by the U.S. Centers for Disease Control and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 25, 2020 Category: Pharmaceuticals Source Type: news

Janssen Announces Health Canada Approval of CABENUVA ™, the First Long-Acting Regimen for the Treatment of HIV
Cork, Ireland, March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that Health Canada has approved CABENUVA™ (cabotegravir and rilpivirine extended release injectable suspensions), the first and only once-monthly, long-acting regimen for the treatment of HIV-1 infection in adults. CABENUVA™ is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]). CABENUVA™, a co-packaged kit with ...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Hepatitis B prophylaxis in adolescents who present for examination after alleged sexual assault - Jones ME, Tully JM.
AIM: In Australia, the risk of hepatitis B virus (HBV) transmission from single sexual contact is low. This, combined with assumed widespread immunity from vaccination, has resulted in a lack of clarity surrounding the necessity for hepatitis B post-exposu... (Source: SafetyLit)
Source: SafetyLit - March 17, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Risk for Liver Cancer Down With Low-Dose Aspirin in Hepatitis B, C
WEDNESDAY, March 11, 2020 -- Low-dose aspirin is associated with a reduced risk for hepatocellular carcinoma among patients with chronic viral hepatitis, according to a study published in the March 12 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 11, 2020 Category: Pharmaceuticals Source Type: news

For People With Hepatitis, Daily Aspirin Might Lower Liver Cancer Risk
WEDNESDAY, March 11, 2020 -- People with hepatitis B or C are at greater risk for liver cancer, but a low-dose aspirin a day might significantly lower that risk, a new study suggests. Over a median of nearly eight years of follow-up, 4% of those... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 11, 2020 Category: General Medicine Source Type: news

Princeton researchers identify factors essential for chronic hepatitis B infection
(Princeton University) A study published in the journal Nature Microbiology identified factors that the hepatitis B virus uses when establishing long-term infection in the liver. The findings could help lead to treatment strategies for chronic HBV infection, a condition that increases the risk of developing liver cancer and is responsible for almost 900,000 deaths worldwide each year. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 9, 2020 Category: Infectious Diseases Source Type: news

FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma
Basel, 4 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the Elecsys ® GALAD score.* This algorithmic score combines gender and age with the biomarker results of the Elecsys AFP, AFP-L3 and PIVKA-II and is intended to aid diagnosis of early stage hepatocellular carcinoma (HCC). Dr. Amit Singal, Medical Director of the Liver Tumor Program   and Clinical Chief of Pathology at UT Southwestern Medical Center in Dallas, USA, stated, " HCC is the fourth leading cause of cancer-related death worldwide, wit...
Source: Roche Investor Update - March 4, 2020 Category: Pharmaceuticals Source Type: news

Licensure of a New Hexavalent Vaccine for Use in Infants Licensure of a New Hexavalent Vaccine for Use in Infants
A new hexavalent vaccine for use in children aged 6 weeks through 4 years has been approved by the FDA to prevent diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, and hepatitis B.Morbidity & Mortality Weekly Report (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 2, 2020 Category: Allergy & Immunology Tags: Public Health & Prevention Journal Article Source Type: news

HBV: Rethink the Free Pass for Immune-Tolerant Patients HBV: Rethink the Free Pass for Immune-Tolerant Patients
There might well be a cure for hepatitis B in coming years, just like there is now for hepatitis C, an expert reports.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 27, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Gut Microbiota Dysbiosis in HBV-induced Chronic Liver Disease Gut Microbiota Dysbiosis in HBV-induced Chronic Liver Disease
Using a gene sequencing approach, this study examined the gut microbiota profile of patients with hepatitis B virus-induced chronic liver disease compared with healthy controls.Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 18, 2020 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news